Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
Reblozyl flops in a new anaemia use
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Adcom puts up a Blenrep roadblock
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
Boehringer slims down in SIRPα
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
